Leading cancer research Institute partner with Boehringer Ingelheim to advance the translational science for development of innovative new lung and colorectal cancer therapeutics
- Published date:
- May 16 2022
The Cancer Research UK Manchester Institute Cancer Biomarker Centre (CBC) at The University of Manchester is delighted to announce a substantive collaborative partnership with Boehringer Ingelheim, a leading research-driven biopharmaceutical company, to support the development of innovative cancer therapeutics for lung and colorectal cancers with translational sciences.
The Cancer Research UK Manchester Institute Cancer Biomarker Centre (CBC) at The University of Manchester is delighted to announce a substantive collaborative partnership with Boehringer Ingelheim, a leading research-driven biopharmaceutical company, to support the development of innovative cancer therapeutics for lung and colorectal cancers with translational sciences.
The partnership will embrace the synergies in drug discovery and development with translational expertise and will drive forward target distribution studies, optimise primary co-cultures for targeted and immuno-therapy efficacy testing, and seek predictive biomarkers of therapy response.
The CBC is currently recruiting 10 staff to deliver the exciting program of joint research with Boehringer Ingelheim in the coming 5 years.
Professor Caroline Dive, Director of the CBC said “We are really excited to start working with translational scientists in Boehringer Ingelheim to advance new therapies to the clinic targeting unmet needs of patients with lung or colorectal cancers, with clinic ready biomarkers to select those most likely to respond, with option to extend to additional cancer indications.”
Tony Hickson, Chief Business Officer at Cancer Research UK said: “We are delighted to collaborate with Boehringer Ingelheim and have no doubt that the expertise the Cancer Biomarker Centre will provide over the next 5 years of the collaboration will be invaluable to both our and Boehringer Ingelheim’s ambitions to develop much-needed new treatment options for patients with lung or colorectal cancer.”
Professor Graham Lord, Vice-President and Dean of the Faculty of Biology, Medicine and Health at University of Manchester said: “This collaboration is an important step for our programme of research and may lead to the development and delivery of new and more effective therapeutics for patients with lung and colorectal cancers driven by translational findings. It supports all three of the Faculty Grand Challenges; novel mechanisms of disease, prevention and early detection and next generation therapeutics”
Notes to editor
About Cancer Research UK
- Cancer Research UK is the world’s leading cancer charity dedicated to saving lives through research
- Cancer Research UK’s pioneering work into the prevention, diagnosis and treatment of cancer has helped save millions of lives.
- Cancer Research UK receives no government funding for its life-saving research. Every step it makes towards beating cancer relies on every donation made.
- Cancer Research UK has been at the heart of the progress that has already seen survival in the UK double in the last 40 years.
- Today, 2 in 4 people survive their cancer for at least 10 years. Cancer Research UK’s ambition is to accelerate progress so that by 2034, 3 in 4 people will survive their cancer for at least 10 years.
- Cancer Research UK supports research into all aspects of cancer through the work of over 4,000 scientists, doctors and nurses.
- Together with its partners and supporters, Cancer Research UK's vision is to bring forward the day when all cancers are cured.
For further information about Cancer Research UK's work or to find out how to support the charity, please call 0300 123 1022 or visit www.cancerresearchuk.org. Follow us on Twitter and Facebook.
About The University of Manchester
The University of Manchester, a member of the prestigious Russell Group, is one of the UK’s largest single-site university with more than 40,000 students – including more than 10,000 from overseas. It is consistently ranked among the world’s elite for graduate employability. The University is also one of the country’s major research institutions, rated fifth in the UK in terms of ‘research power’ (REF 2014). World-class research is carried out across a diverse range of fields including cancer, advanced materials, global inequalities, energy and industrial biotechnology.